Bristolmyers Squibbs 2q Earnings Beat Street On Healthy Sales Of Its Blockbuster Cancer Drug Opdivo | Latest News RSS feed

Bristolmyers Squibbs 2q Earnings Beat Street On Healthy Sales Of Its Blockbuster Cancer Drug Opdivo - Latest News


Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo

Bristol-Myers Squibb Co (NYSE:BMY) reported second-quarter earnings Thursday that topped Wall Street estimates on strong sales of its blockbuster cancer drug Opdivo and blood thinner Eliquis. For the ... read more

Late Movers: Merck drops after downgrade from BMO Capital Markets

READ: Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda Bristol-Myers Squibb Co (NYSE:BMY) shares headed south as the drug company withdrew an application to the US Food ... read more

Bristol-Myers beat on earnings thanks to sales of its drugs that use the immune system to treat cancer

NEW YORK (Reuters) - Bristol-Myers Squibb ... for blockbuster Opdivo as well as pressure from activist investors, also raised its expectations for its full-year earnings, reversing a cut to its ... read more

Looking for another news?


Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene

Bristol-Myers Squibb (NYSE:BMY) reported very good fourth-quarter results on Thursday. Revenue jumped 10% year over year, with strong growth for blockbuster drugs Opdivo and Eliquis leading the way. ... read more


The day has come: Merck’s Keytruda surpasses Bristol-Myers Squibb’s Opdivo in Q2 sales

Merck & Co.’s blockbuster cancer drug Keytruda has delivered again in the second quarter, and this time, it has seized the PD-1/L1 crown from Bristol-Myers Squibb’s archrival, Opdivo ... Human Health, ... read more

Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda

READ: Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo Shares in Merck traded flat, slightly down to US$63.84 in premarket trade. “Strong ... read more

Bristol-Myers Tops Q4 Earnings, Pulls FDA Application for Cancer Combination

Bristol-Myers Squibb Co. (BMY) posted stronger-than-expected fourth quarter-earnings Thursday but pulled an application to the U.S. Food & Drug Administration for a blockbuster ... market approval for ... read more

Bristol-Myers boosts profit outlook on strong cancer-drug sales

Drugmaker Bristol-Myers Squibb raised its full-year earnings outlook on Thursday after third-quarter results handily beat Wall Street’s expectations driven by soaring sales for drugs ... were led by ... read more

Keytruda sales power Merck to quarterly beat

Revenue from the cancer drug ... sales, helped by its expanded approval to treat various forms of cancer. Sales of Bristol-Myers Squibb's Opdivo surged 34 percent to $1.51 billion in the latest ... read more

Cancer’s Six-Figure Blockbuster Hopefuls Aid Drugmaker Sales

Pfizer Inc., Merck & Co. and Bristol-Myers Squibb Co. all beat Wall Street’s earnings projections in the first quarter, with sales of their ... The U.S. Food and Drug Administration also approved ... read more

3 Things to Really Like About Bristol-Myers Squibb's Q4 Earnings Results

The drugmaker also beat Wall Street estimates with its bottom-line result. BMS announced non-GAAP net earnings ... for Opdivo, which is on track to become the No. 2 best-selling cancer drug in the ... read more

Cancer's blockbusters aid drugmakers' sales

Pfizer Inc., Merck & Co., and Bristol-Myers Squibb Co. all beat Wall Street's earnings projections in the first quarter, with sales of their ... The U.S. Food and Drug Administration also approved ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us